You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博安生物(06955.HK)擬折價13.88%配售3840萬股 總籌4億港元主攻創新藥研發

格隆匯6月4日丨博安生物(06955.HK)發佈公告,2025年6月3日,公司及配售代理(即瑞銀集團)訂立配售協議,據此,公司同意委任配售代理,而配售代理同意作爲公司的代理促使買方按配售價竭誠購買配售股份,惟須遵守配售協議所載條款及受當中所載條件規限。

可能根據配售事項出售的配售股份總數爲3840萬股,相當於本公告日期的已發行股份總數約7.17%;及經配發及發行配售股份擴大的已發行股份總數約6.69%。配售價每股10.42港元較股份於最後交易日在聯交所所報收市價每股12.100港元折讓約13.88%。

假設總計3840萬股配售股份將獲出售,配售事項所得款項總額預期將約爲4億港元。預期配售事項所得款項淨額約爲3.96億港元。公司擬將配售事項的所得款項淨額用作以下用途:(a)約50%將用於創新候選產品的研發,包括:(i)BA1106(CD25抗體)、BA1301 (Claudin18.2 ADC)及BA1302 (CD228 ADC)的臨牀試驗;(ii)BA1304(EGFR/B7H3雙特異性ADC)及PR201(PD-1/IL-2掩蔽抗體)的非臨牀研究及臨牀試驗;及(iii)其他具有市場潛力的創新候選產品的概念驗證;(b)約20%將用於已上市及即將上市產品的商業化;及(c)約30%將用於補充公司營運資金及一般企業用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account